Evoke Wealth’s Summit Therapeutics SMMT Stock Holding History

Evoke Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,668	Closed	-$202K	–	542
2026 Q1	$202K	Sell	10,668 -384	-3%	-$6.21K	﹤0.01%	671
2025 Q4	$193K	Sell	11,052 -2,339	-17%	-$44K	﹤0.01%	643
2025 Q3	$277K	Buy	13,391 +63	+0.5%	+$1.53K	0.01%	518
2025 Q2	$284K	Sell	13,328 -86	-0.6%	-$1.96K	0.01%	465
2025 Q1	$259K	Sell	13,414 -1,586	-11%	-$31.8K	0.01%	380
2024 Q4	$268K	Hold	15,000	–	–	0.01%	363
2024 Q3	$329K	Buy	+15,000	New	+$210K	0.01%	321
2023 Q3	–	Sell	-25,218	Closed	-$63.3K	–	401
2023 Q2	$63.3K	Hold	25,218	–	–	﹤0.01%	357
2023 Q1	$44.1K	Buy	+25,218	New	+$68.8K	﹤0.01%	344
2022 Q4	–	Sell	-8,000	Closed	-$10K	–	1022
2022 Q3	$10K	Buy	8,000 +3,000	+60%	+$3.39K	﹤0.01%	757
2022 Q2	$5K	Buy	+5,000	New	+$7.01K	﹤0.01%	902
2021 Q4	–	Sell	-3,200	Closed	-$16K	–	1235
2021 Q3	$16K	Hold	3,200	–	–	﹤0.01%	672
2021 Q2	$24K	Buy	+3,200	New	+$21K	﹤0.01%	626

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Evoke Wealth's SMMT Position: Q2 2026 in Review

Evoke Wealth sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 10,668 shares — an estimated $202K sold.

Evoke Wealth first reported a position in SMMT in Q2 2021 and held it in 13 quarters. The position peaked at $329K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Evoke Wealth reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Evoke Wealth sold 10,668 Summit Therapeutics shares in Q2 2026, an estimated $202K.
Evoke Wealth first reported a position in Summit Therapeutics in Q2 2021 and held it in 13 quarters.
Evoke Wealth's Summit Therapeutics position peaked at $329K in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Evoke Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.